TARS250117C35000
- 12.30
- 0.000.00%
Tarsus Pharmaceuticals Newsroom
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $72
Tarsus Pharmaceuticals Analyst Ratings
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $84
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $65
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $65
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $65 to $84
Tarsus Pharmaceuticals Is Maintained at Neutral by Goldman Sachs
Tarsus Pharmaceuticals Analyst Ratings
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $60
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $63
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Neurocrine (NBIX) and Tarsus Pharmaceuticals (TARS)
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $67
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $63
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $63